Division Chief of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Dell Medical School, the University of Texas , Austin, TX, USA.
Expert Rev Mol Diagn. 2020 Dec;20(12):1171-1181. doi: 10.1080/14737159.2020.1858054. Epub 2020 Dec 10.
: Fibromyalgia represents the most prevalent of the group of conditions that are known as central sensitivity syndromes. Approximately 2-5% of the adult population in the United States is affected by Fibromyalgia. This pain amplification syndrome has an enormous economic impact as measured by work absenteeism, decreased work productivity, disability and injury compensation, and over-utilization of healthcare resources. Multiple studies have shown that early diagnosis of this condition can improve patient outlook, and redirect valuable health care resources toward more appropriate targeted therapy. Efforts have been made toward improving diagnostic accuracy through updated criteria. : Reviewed here are 1) reasons for the need for more accurate diagnosis of Fibromyalgia, (2) a review of the evolution of Fibromyalgia to current times, and (3) the proliferation of currently available diagnostic criteria and problems related to each of them. From initial literature review until October 2020, PubMed, Embase, and Scopus were searched for applicable literature. : A discussion of ongoing efforts to obtain a biomarker to enhance diagnostic accuracy concludes this review. A need to include rheumatologists as part of the care team of patients with Fibromyalgia is emphasized.
纤维肌痛是一组被称为中枢敏化综合征的疾病中最常见的一种。在美国，大约有 2-5%的成年人受到纤维肌痛的影响。这种疼痛放大综合征对工作缺勤、工作生产力下降、残疾和伤害赔偿以及过度利用医疗保健资源等方面造成了巨大的经济影响。多项研究表明，早期诊断这种疾病可以改善患者的前景，并将宝贵的医疗保健资源转向更合适的靶向治疗。已经通过更新的标准努力提高诊断的准确性。
1）需要更准确诊断纤维肌痛的原因；2）回顾纤维肌痛的演变过程；3）目前可用的诊断标准的大量增加，以及它们各自存在的问题。从最初的文献综述到 2020 年 10 月，在 PubMed、Embase 和 Scopus 上搜索了相关文献。本文讨论了为提高诊断准确性而正在进行的获取生物标志物的努力，并强调需要将风湿病学家纳入纤维肌痛患者的治疗团队。
